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Abstract
Background: The purpose of this study was to investigate the role of malignant ascites tumor microenvironment
in ovarian cancer progression and chemoresistance.
Methods: A total of 45 patients with ovarian cancer and three benign ascites were collected at the time of clinical
intervention. Ascites cholesterol levels were quantitated using cholesterol quantitation kit and recurrence free
survival (RFS) of ovarian cancer patients were collected. The sensitivity of ovarian cancer cells to cisplatin (CDDP)
and paclitaxel (PAC) were assessed by viability assay, flow cytometry and protein expression. Receiver operating
characteristics (ROC) curve and Youden index analysis were applied to calculate the optimal cut-off values for
ascites cholesterol. Kaplan-Meier curve were applied to compare RFS between high and low ascites cholesterol
levels in ovarian cancer patients.
Results: Here we show that cholesterol is elevated in malignant ascites and modulates the sensitivity of ovarian
cancer cells to CDDP and PAC by upregulating the expression of drug efflux pump proteins, ABCG2 and MDR1,
together with upregulation of LXRɑ/β, the cholesterol receptor. Transfection of LXRɑ/β siRNA inhibited cholesterol-
induced chemoresistance and upregulation of MDR1. In addition, the cholesterol level in malignant ascites was
negatively correlated with number of CDDP-induced apoptotic cell death, but not with that of PAC-induced
apoptotic cell death. Cholesterol depletion by methyl beta cyclodextrin (MβCD) inhibited malignant ascites-induced
chemoresistance to CDDP and upregulation of MDR1 and LXRɑ/β. For patients with ovarian cancer, high
cholesterol level in malignant ascites correlated with short RFS.
Conclusions: High cholesterol in malignant ascites contributes to poor prognosis in ovarian cancer patients, partly
by contributing to multidrug resistance through upregulation of MDR1 via activation of LXRɑ/β.
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Background
Ovarian cancer is the most lethal gynecologic cancer
resulting from the late diagnosis and eventual chemore-
sistance followed by frequent recurrence [1]. Standard
treatment of ovarian cancer includes, maximal cytore-
ductive surgery and adjuvant taxane and platinum based
chemotherapy. Initial response rate is very high, 70–80%
including 40 to 50% complete response, but majority of
patients relapse within 2 years with subsequent resist-
ance to chemotherapy [2]. Despite recent advances in
anticancer therapy of ovarian cancer, ovarian cancer sur-
vival remains poor and our understanding of ovarian
cancer progression including chemoresistance is still
very limited.
There is a growing evidence indicating the importance of
tumor microenvironment in ovarian cancer progression, es-
pecially chemoresistance [3]. The aberrant accumulation of
fluid in the peritoneal cavity called ascites formation occurs
in more than one third of ovarian cancer patients and in al-
most all recurrent cases [2, 4]. Recent progress in decipher-
ing the cellular and acellular components of ascites has
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shown that ascites serves as an important tumor microenvir-
onment enriched in pro-tumorigenic signals that contribute
to enhanced invasiveness and chemoresistance [5, 6]. More-
over, the presence of ascites correlates with the disease stage
and poor prognosis in ovarian cancer patients [7, 8]. It is crit-
ical to elucidate the mechanism of chemoresistance to im-
prove the survival rate for ovarian cancer.
Previous studies have shown that cholesterol is signifi-
cantly elevated in ascites and could be used as a marker for
malignant ascites [9, 10]. Additionally cholesterol has been
shown to be involved in the regulation of drug response in a
number of cancer models [11, 12]. Cholesterol is required
for cellular signals including proliferation. However, an ex-
cess cellular cholesterol is toxic and thus the levels of choles-
terol are tightly regulated and coupled to pathways that
enable the removal of cholesterol [13, 14]. The transcription
factors of the liver X receptor (LXR) family provide a
feed-forward regulatory system for the elimination of excess
cholesterol [15]. Recently, LXRα was reported to exhibit
oncogenic properties in gastric cancer cells [16]. There is no
study about the relationship between the cholesterol in ma-
lignant ascites and chemoresistance in ovarian cancer. Our
objective is to know the effect of malignant ascites choles-
terol on chemoresistance and explore the mechanism of che-
moresistance by the cholesterol in ascites. Our present study
reveals that the cholesterol is elevated in malignant ascites
derived from ovarian cancer patients and correlates with the
chemoresistance and reduced recurrence free survival (RFS).
In addition, cholesterol enhances chemoresistance to cis-
platin (CDDP) and paclitaxel (PAC) via Liver x receptor α/β
(LXRα/β) mediated induction of multidrug resistance protein
expression, MDR1 protein in vitro.
Methods
Cell culture, clinical samples and reagents
PA-1, OVCAR-3, and SKOV-3 used in this study were ob-
tained from the American Type Culture Collection (Rock-
ville, MD). With the exception of PA-1, these cell lines were
grown in RPMI1640 (WelGENE, Seoul, Korea). PA-1 was
cultured in MEM (WelGENE, Seoul Korea). All culture
media were supplemented with 10% FBS (Gibco-BRL,
Gaithersberg, MD), and 100 μg/mL penicillin-streptomycin
(P/S) (Invitrogen, Carlsbard, CA).
Ascites from 30 serous, 6 mucinous, 6 clear and 3 mixed
ovarian cancer patients and three benign ascites were col-
lected at the time of clinical intervention at the Seoul Na-
tional University Hospital (Seoul, Korea). This study was
approved by the Institutional Review Board (IRB) at Seoul
national University Hospital (Registration number: 1409–
1540-616), and prior written and informed consent was ob-
tained from every patient. Ascites were centrifuged at 2500
rpm for 20min. The acellular fractions were filtered (70 μm),
aliquoted and stored at − 80 °C to minimize freeze-thaw.
Cell viability assay
Cell viabilities were evaluated by the Thiazolyl blue tetrazo-
lium bromide (MTT) assay. Cells were seeded in 96-well
plate. After overnight incubation, an increasing cisplatin
(CDDP) concentration from 0 to 20 μM were adjusted to a
final volume of 100 μl/well for indicated time. The cells were
incubated with 50 μL MTT (2mg/ml, 3 h, 37 °C) in 5% CO2
in humidified atmosphere and subsequently solubilized in
DMSO 100 μl/well. The optical density at 540 nm was deter-
mined using an enzyme linked immunosorbent assay reader.
Cell death analysis
Using flow cytometry analysis, apoptotic cell death was de-
termined via Annexin-V and PI staining (BD Pharmingen,
CA) according to the manufacturer’s protocol.
Western blotting
Protein lysates were prepared as described previously [11].
In brief, after cell extraction, proteins were separated by
SDS/PAGE (6–15% gel, depending on specific protein
assessed) followed by electrotransfer onto nitrocellulose
membranes and probed with the indicated antibodies.
Reagents and antibodies
Stock solutions of cisplatin (Enzo life science) and paclitaxel
(LC Laboratories,) were prepared in Dimethylformamide;
0.001% and water soluble cholesterol and methyl
β-cyclodextrin (MβCD) (Sigma-Aldrich, St. Louis, MO) were
prepared in DEPC water and used at the final concentration
indicated. MTT was from Amresco (Olon, OH). Antibodies
to ABCG2 (monoclonal, 1:1000 dilution), PARP (polyclonal,
1:1000 dilution), LXRα/β (monoclonal, 1:1000 dilution) and
Lamin B (polyclonal, 1:5000 dilution) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to
MDR1 (monoclonal, 1:1000 dilution), pan Cadherin (poly-
clonal, 1:1000 dilution) were purchased from Cell Signaling
(Danvers, MA). GAPDH (monoclonal, 1:5000 dilution) (AB
frontier) and α tubulin (monoclonal, 1:5000 dilution) (Santa
Cruz, CA) were used as a loading control.
Nuclear and cytoplasmic protein extraction
Using NE-PER nuclear and cytoplasmic extraction reagents
from Pierce Biotechnology (Rockford, USA), cytoplasmic
and nuclear proteins were separated and extracted from can-
cer cells, according to the manufacturer’s protocol.
Membrane and cytoplasmic protein extraction
Using Membrane Protein Extraction Kit from BioVision
(Milpitas, CA), membrane and cytoplasmic proteins
were separated and extracted from cancer cells, accord-
ing to the manufacturer’s protocol.
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Small interfering RNA transfection
The siRNA-targeting LXRα (sc-38,828) purchased from
Santa Cruz and scrambled RNA (mBio Tech, Gyeonggido,
Korea) was used as a negative control. Cells were trans-
fected using RNAi reagent obtained from Invitrogen
(Carlsbad, CA), according to the manufacturer’s protocols.
Ascites cholesterol quantitation
Ascites cholesterol level were quantitated using cholesterol
quantitation kit (Sigma-Aldrich, St. Louis, MO). Ascites were
diluted 5–10% to that of final volume, and the cholesterol
level were quantitated according to the manufacturer’s
protocol. Serum ascites cholesterol gradient (SACG) was cal-
culated as Serum Cholesterol – Ascites Cholesterol.
Cignal reporter assay
Cells were plated on a 96-well plate. Cignal LXR reporter
(Qiagen) 100 ng was transfected using Lipofectamine 2000™
reagent obtained from Invitrogen (Carlsbad, CA), according
to the manufacturer’s protocols. At 24 h post-transfection, cells
were treated either with or without cholesterol. At 6 h after
cholesterol treatment, cells were harvested and reporter assays
were performed using a dual luciferase reporter assay system
(Promega) according to the manufacturer’s instructions.
Renilla and firefly luciferase activities were measured using
Luminescence Counter VICTOR™ Light (Perkin Elmer, NJ).
Primary cell isolation from ovarian cancer patient derived
ascites
Primary cells were isolated and cultured as previously
described [17]. In brief, ascites derived from ovarian can-
cer patients were centrifuged at 2500 rpm for 10min.
Cells were re-suspended in PBS and cells were isolated
using Ficoll-Paque™-PREMIUM centrifugation at 2500
rpm for 30 min. The collected cells were cultured in the
complete culture medium.
Statistical analysis
Data were presented as mean± SEM of triplicate experiments.
One-way ANOVA and, when appropriate, Student’s t-test
were used for statistical analyses. Significant difference among
experimental groups was analyzed by Scheffe’s post hoc test.
Receiver operating characteristics (ROC) curve and Youden
index analysis were performed to determine the optimal
cut-off values for ascites cholesterol. All analyses were con-
ducted using IBM SPSS statistics 21 (SPSS Inc., Chicago, IL).
P values of < 0.05 were considered statistically significant.
Results
Response of ovarian cancer cell lines to CDDP and PAC
correlates with ABCG2 and MDR1 protein expression
CDDP and PAC treatment causes a dose- and time-
dependent decrease in cell viability of three ovarian cancer
cell lines, PA-1, OVCAR-3 and SKOV-3 cells and CDDP
IC50 was calculated to be 1.4 μM, 6.5 μM and 12 μM re-
spectively and PAC IC50 was calculated to be 10.5 nM,
14.3 nM and 24.5 nM respectively (Fig. 1a). In ovarian can-
cer, expression of ATP-binding cassette transporter (ABC
transporter) proteins including ABCG2 and MDR1 are closely
related with drug resistance [18, 19]. More than half the family
members of ABC transporter confer drug resistance [20]. Of
those ABCG2 and MDR1 are modulated by cholesterol and
cholesterol synthesis inhibitor, statins [11, 12, 21, 22]. Indeed,
ABCG2 and MDR1 protein expression were relatively high in
SKOV-3 compared to PA-1 and OVCAR-3 (Fig. 1b) and IC50
to CDDP and PAC were directly correlated with ABCG2 and
MDR1 protein expression (Fig. 1c and d).
Cholesterol enhances chemoresistance to CDDP and PAC
through reduction in apoptosis
Circulating free cholesterol levels are tightly regulated and
cholesterol have been shown to be involved in the regulation
of various membrane proteins, including ABCG2 [11, 12].
Moreover, lowering cholesterol synthesis with HMG-CoA re-
ductase inhibitor reduced ovarian cancer risk [23–25]. To ex-
plore the role of cholesterol in ovarian cancer
chemoresistance, we applied various concentration of
water soluble cholesterol (CHO) containing media
(0, 5, 10, 20 μg/ml). Ovarian cancer cells were pre-
treated with an indicated cholesterol concentration
for 24 h and cell viability were determined using
MTT assay (Additional file 1: Figure S1A). To ensure
that cholesterol loading vehicle, methyl-β-cyclodex-
trin (MβCD), depleting cholesterol in solution has
no toxicity, at the indicated concentration of MβCD
after 24 h treatment (Additional file 1: Figure S1B).
For all subsequent experiments, 5 μg/ml cholesterol
was used with no significant effect on cell viability
of ovarian cancer cells. Cholesterol pretreatment sig-
nificantly increased IC50 to CDDP and PAC in PA-1
and SKOV-3 cells, not in OVCAR-3 cells (Fig. 2a
and Additional file 1: Figure S2). This was further
confirmed with ascites derived ovarian cancer cells,
A8, A39 and A53 at passage between 14 and 18
(Additional file 1: Figure S2). Accordingly, cholesterol
treatment increased the expression of ABCG2 and MDR1
protein in PA-1 and SKOV-3 cells but to a less extent in
OVCAR-3 cells (Fig. 2b). Notably, cholesterol pretreatment
significantly reduced both CDDP and PAC induced apop-
totic cell death only in PA-1, verified by Annexin V/PI stain-
ing Fig. 2 C1 and C2. Cholesterol pretreatment significantly
reduced CDDP mediated cleaved PARP expression only in
PA-1 and SKOV-3 and PAC mediated cleaved PARP expres-
sion only in PA-1 and OVCAR-3, analyzed by Western blot
(Fig. 2 C3 and C4). Altogether, cholesterol enhances che-
moresistance to CDDP and PAC in ovarian cancer cells.
PA-1 cells were chosen for further evaluation of molecular
mechanisms of cholesterol-induced drug resistance.
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LXRα/β mediates cholesterol-induced chemoresistance in
ovarian cancer
Cholesterol is an essential components of mammalian cell
membranes, which generates a semipermeable barrier be-
tween cellular compartments and modulates the functions of
membrane proteins [26]. Circulating cholesterol levels are
tightly regulated as excess cholesterol is toxic [14]. The liver x
receptor (LXR) family, provide a feed-forward regulatory sys-
tem for the elimination of excess cholesterol, positively regu-
lating the expression of genes encoding lipid transport
proteins [13, 15]. Moreover, previous report suggests choles-
terol as an essential modulator of the ABCG2 and MDR1
functions [22]. Interestingly, LXRα/β protein expression was
relatively high in SKOV-3 compared to PA-1 and OVCAR-3
(Fig. 3a) and IC50 to CDDP and PAC were directly correlated
with LXRα/β protein expression (Fig. 3b). Cholesterol treat-
ment increased the expression of LXRα/β protein in PA-1 and
ascites derived ovarian cancer cells, A8, A39 and A53 (Fig. 3c
and d). We also found that MDR1 but not ABCG2 protein
expression was positively correlated with LXRα/β in primary
cells isolated from ovarian cancer patient derived ascites at
passage 0 (Additional file 1: Figure S3E). Information of pri-
mary cancer cells are shown in Additional file 2: Table S1.
Using PA-1 cell line, we further evaluated the role of
LXRα/β protein and cholesterol in chemoresistance.
Treatment of cholesterol for 24 h increased membrane
expression of both ABCG2 and MDR1 and nuclear
translocation and transcriptional activity of LXRα/β in
PA-1 (Fig. 4a). Silencing LXRα/β with siRNA impaired
cholesterol–induced MDR1 overexpression but did not
affect ABCG2 overexpression, confirmed by Western
blotting using whole cell lysate, membrane and nuclear
fraction (Fig. 4b). Also, silencing LXRα/β significantly
decreased cholesterol induced chemoresistance (Fig. 4c).
Fig. 1 ABCG2 and MDR1 protein expression is correlated with resistance to cisplatin and paclitaxel in ovarian cancer cells. (A1 and A2) Comparison of ovarian
cancer cell viability following CDDP and PAC treatment for 48 h. a and b) The indicated concentrations of CDDP and PAC were treated to three ovarian cancer
cell lines for 48 h. Cell viability was determined by MTT assay. b ABCG2 and MDR1 protein expression was measured by Western blot. c-d. Protein expression
levels were quantitated by densitometry and normalized to GAPDH. The ratio of densities was calculated using PA-1 as control. The correlation between CDDP
IC50 and ABCG2/MDR1 protein expression, PAC IC50 and ABCG2/MDR1 protein expression were determined by simple linear regression analysis. The
correlation coefficient square (R2) was determined by Pearson’s correlation coefficient test
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Clinical implication of high cholesterol in ascites and
LXRα/β in ovarian cancer development and cancer
progression
The cholesterol level is significantly higher in malignant asci-
tes, which can be used to discriminate malignant ascites
from benign ascites [9, 10]. We postulated that cholesterol in
malignant ascites from patients with advanced ovarian
cancer modulate response to CDDP and PAC, causing ther-
apy failure in ovarian cancer patients with ascites. Forty-five
ascites were collected from ovarian cancer patients and three
from benign conditions. The patient characteristics of malig-
nant group are shown in Additional file 3: Table S2 and non-
malignant group in Additional file 4: Table S3. Both total and
free cholesterol levels in ascites were quantitated using
Fig. 2 Increase of CDDP and PAC resistance after a 24 h exposure of cholesterol in ovarian cancer cell lines. Ovarian cancer cell lines were
pretreated with 5 μg/ml cholesterol for 24 h. (A1) Comparison of IC50 to CDDP and (B2) PAC before and after cholesterol treatment, determined
from the data by MTT assay. b Expression of ABCG2 and MDR1 protein 24–48 h after 5 μg/ml cholesterol treatment by Western blot. (C1 and C2)
Number of apoptotic cells induced by CDDP and PAC, determined by Annexin V/PI staining. (C3 and C4) Protein expression of cleaved PARP by
Western blot and densitometry analysis of cleaved PARP relative to α tubulin. Significant differences are indicated as follows. *P < 0.05,
**P < 0.01, ***P < 0.001
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cholesterol quantitation kit and serum cholesterol levels were
simultaneously checked. The cholesterol level was significantly
higher in malignant ascites than in peritoneal fluid from pa-
tients with benign ovarian cyst (Fig. 5 A1). The serum ascites
cholesterol gradient (SACG, calculated as serum cholesterol
subtracted by ascites cholesterol) levels were significantly
lower in ovarian cancer patients than in benign patients
(Fig. 5 A2). To determine the role of cholesterol in malig-
nant ascites, patients were divided into two groups depend-
ing on the levels of cholesterol with high cholesterol group
equal to or greater than 70mg/dL in ascites and low
cholesterol group less than 70mg/dL. The optimal cut-off
value 70mg/dL was derived from a ROC curves and a You-
den index analysis (data not shown). The ascites cholesterol
levels from three representing patients of each group are
shown in Fig. 5 B1. Treatment with ascites of low and high
cholesterol group increased the expression of MDR1 and
LXRα/β expression in PA-1 cell lysate (Fig. 5 B2). Interest-
ingly, ascites pretreatment significantly reduced CDDP
and CDDP in combination with PAC induced apoptotic
cell death but did not when PAC were treated alone in
PA-1 cells (Fig. 5 B3, B4 and Additional file 1: Figure S3).
Fig. 3 LXRα/β protein expression is correlated with resistance in ovarian cancer cells. a LXRα/β protein expression was measured by Western blot. (B1 and B2)
Protein expression levels were quantitated by densitometry and normalized to GAPDH. The ratio of densities was calculated using PA-1 as control. The
correlation between CDDP IC50 and LXRα/β protein expression, PAC IC50 and LXRα/β protein expression was determined by simple linear regression analysis.
c Expression of LXRα/β protein after cholesterol (5 μg/ml) treatment measured by Western blot. d Expression of ABCG2, MDR1 and LXRα/β protein was
measured by Western blot with cholesterol (5 μg/ml) treatment in ascites derived ovarian cancer cells. (E1 and E2) LXRα/β protein expression levels were
measured by Western blot in primary cancer cells isolated from ovarian cancer patient derived ascites. Protein expression levels were quantitated by
densitometry and normalized to GAPDH. The correlation coefficient square (R2) was determined by Pearson’s correlation coefficient test
Kim et al. BMC Cancer         (2018) 18:1232 Page 6 of 12
In parallel, cholesterol levels in ascites were inversely cor-
related with the number of CDDP induced apoptotic cell
death and marginally when CDDP were treated in com-
bination with PAC but not with that of PAC induced
apoptotic cell death in PA-1 cells (Fig. 5 B5, B6 and Add-
itional file 1: Figure S3).
To further confirm that the chemoresistance is acquired
due to the enriched cholesterol microenvironment, cholesterol
was depleted with methyl beta cyclodextrin (MβCD) [27].
Co-treatment of malignant ascites with MβCD for 24 h signifi-
cantly reduced MDR1 and LXRα/β expression (Fig. 6a). More
importantly, co-treatment of malignant ascites with MβCD
Fig. 4 Silencing of LXRα/β inhibits cholesterol-induced chemoresistance. PA-1 cell line was pretreated with 5 μg/ml cholesterol for 24 h. (A1)Western blot
of ABCG2, MDR1 in cytosol and membrane fraction. (A2) Western blot of LXRα/β in cytosol and nuclear fraction. (A3) Transcriptional activity of LXRα/β
determined by luciferase reporter gene assay. b-c Effect of LXRα/β silencing by siRNA transfection on cholesterol-induced chemoresistance. PA-1 cells were
transfected with LXRα/β targeted siRNA or scrambled siRNA (80 nM) as a negative control. Then PA-1 cells were treated with CDDP or PAC in the presence
or absence of cholesterol. (B1) Expression of ABCG2, MDR1 and LXRα/β protein using whole cell lysates, (B2) cytosol and membrane fractions, (B3) cytosol
and nucleus. (B4) Transcriptional activity of LXRα/β. © CDDP- and PAC- induced apoptotic cell death determined by Annexin V/PI staining. Significant
differences are indicated as follows. **P< 0.01, ***P< 0.001
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significantly decreased CDDP induced apoptotic cell death
but did not PAC-induced apoptotic cell death (Fig. 6 B1 and
B2). These data support an important role of the cholesterol
in malignant ascites induced resistance in ovarian cancer.
To know the clinical implication of elevated cholesterol in
malignant ascites, recurrence free survival (RFS) duration
was compared between ovarian cancer patients with ascites
cholesterol levels < 70mg/dL and ≥ 70mg/dL. The mean
values of RFS were 21 and 14months in ascites cholesterol
levels < 70mg/dL and ≥ 70mg/dL groups, showing marginal
significance (p = 0.077) (Fig. 7). Together, these results sug-
gest that elevated cholesterol in ascites may be associated
with the chemoresistance in ovarian cancer patients. Collect-
ively, we show that cholesterol activate LXRα/β in ovarian
cancer cells, causing the chemoresistance to CDDP through
the upregulation of MDR1 expression.
Fig. 5 Cholesterol in ovarian cancer patient derived ascites promotes chemoresistance. (A1) Comparison of cholesterol concentrations between
malignant and benign ascites. (A2) Comparison of serum ascites cholesterol gradient (SACG) between malignant and benign ascites. SACG was
calculated by ascites cholesterol subtracted from serum cholesterol. b Malignant ascites were divided into two groups, low versus high groups,
using an optimal cut-off value calculated from a ROC curve and Youden index analysis. (B1) Cholesterol concentration of benign and malignant
ascites in low vs high group. PA-1 cell line was treated with indicated malignant ascites for 24 h. (B2) Western blot and densitometry analysis of
ABCG2, MDR1 and LXRα/β protein in whole cell lysates. (C = control media without malignant ascites). (B3 and B4) CDDP and PAC induced
apoptotic cell death determined by Annexin V/PI staining 24 h after treatment with each respective malignant ascites. (C = control media without
malignant ascites, black box indicate control without CDDP/PAC treatment) (B5 and B6) Correlation between cholesterol levels in malignant
ascites and relative ratio of number of CDDP- and PAC- induced apoptotic cell death. The correlation coefficient square (R2) was determined by
Pearson’s correlation coefficient test. Significant differences are indicated as follows. *P < 0.05, **P < 0.01, ***P < 0.001
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Discussion
Acquired chemoresistance is the major reason for the failure
of ovarian cancer treatment. Both presence of malignant as-
cites and acquired chemoresistance have been associated
with reduced survival of ovarian cancer patients [28, 29]. In
this study, we demonstrate that ovarian cancer cells exhibit
increased multidrug resistance, such as CDDP and PAC,
when exposed to cholesterol alone or to patient derived ma-
lignant ascites. To our knowledge, our work is the first to
directly demonstrate acquired chemoresistance by choles-
terol in malignant ascites.
As opposed to serum, ascites being a proximal fluid to can-
cer cells themselves provide local tumor microenvironment
rich in many cancer-associated soluble factors [30]. These sol-
uble factors are either cause of or result of underlying disease.
Indeed, the presence of ascites correlates with reduced quality
of life and a poor prognosis in ovarian cancer [8, 31]. Among
soluble factors accumulated in malignant ascites, we found
that cholesterol is significantly higher in malignant ascites
from patients with ovarian cancer than peritoneal fluid from
patients with benign cyst (Fig. 5 A1). This is consistent with
the previous reports by Rana et al. [10]. Moreover, choles-
terol levels in malignant ascites were inversely correlated
with CDDP induced apoptotic cell death but not with
PAC (Fig. 5 B5 and B6). Additionally, high cholesterol in
malignant ascites is associated with shorter RFS (Fig. 7).
Our results suggest that cholesterol in malignant ascites
may play an important role in acquired chemoresistance
to CDDP in ovarian cancer.
Acquired chemoresistance by malignant ascites was first
reported in ovarian cancer-bearing mice model through in-
creased expression and function of ABC transporters [32].
Fig. 6 Cholesterol depletion from malignant ascites by methyl β cyclodextrin (MβCD) inhibits malignant ascites-induced chemoresistance against
CDDP. a Western blot of ABCG2, MDR1 and LXRα/β in whole cell lysates 24 h after co-treatment with malignant ascites and MβCD (cholesterol
depleting agent in solution). (B1 and B2) CDDP and PAC induced apoptotic cell death after co-treatment with malignant ascites and MβCD.
Apoptotic cells determined by Annexin V/PI staining. (Black box indicate control without CDDP/PAC treatment). Significant differences are
indicated as follows. *P < 0.05, **P < 0.01, ***P < 0.001 a, b, c, d, e, f indicates homogeneous subsets, using one-way ANOVA followed by Scheffe’s
post hoc test
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However, a detailed mechanism regulating ABC transporters
in malignant ascites tumor microenvironment is unclear [32,
33]. Cholesterol, a steroidal lipid, occupies about one third of
the plasma membrane lipid content and is an essential com-
ponent of membrane in animal cells [34, 35]. High level of
cholesterol is cytotoxic, therefore should be tightly regulated.
Multiple mechanisms are working, regulating cholesterol up-
take, synthesis and metabolism as well as efflux system oper-
ating for the maintenance of the optimal intracellular
cholesterol concentration [35]. Nevertheless, this regulation
is often dysregulated in cancer, potentially contributing to
hallmarks of cancer including growth, anti-apoptosis and re-
sistance to chemotherapy [36]. Moreover, cholesterol is rich
in cancer cell membranes and has been linked to reduced
sensitivity to platinum-based chemotherapy in lung adeno-
carcinoma [12]. Likewise, clinical significance of cholesterol
in ovarian cancer has been suggested by many recent studies.
The long-term use of statin derivatives, inhibitor of choles-
terol synthesis, has been shown to be associated with re-
duced risk of ovarian cancer development [23–25, 37] and
improved survival for patients with ovarian cancer [38]. In in
vitro studies, statins significantly reduces transporter activity
of ABCG2 or MDR1 but did not expression of mRNA,
through depletion of cellular cholesterol [21]. The transport
functions of both ABCG2 and MDR1 are significantly af-
fected by cellular and membrane cholesterol levels [11, 22,
39–41]. These results and our results have prompted
us to hypothesize that cholesterol enriched in malig-
nant ascites contributes to acquire chemoresistance
in ovarian cancer through upregulation of ABCG2 or
MDR1 protein. Consistent with previous study, our
data reveal that cholesterol alone and malignant as-
cites derived from ovarian cancer patients upregu-
lates the protein expression of ABCG2 and MDR1,
associated with poor prognosis and chemoresistance
in ovarian cancer patients [42–44].
Response to cholesterol treatment was variable among
the three ovarian cancer cell lines we used in this study.
We reasoned that the observed differences are partly
due to the differences in cell lines themselves. PA-1 cell
has been previously shown to be more sensitive to che-
motherapeutics [45]. Cell line difference is hard to de-
fine. In the present study, we found that ABCG2, MDR1
and LXRα/β protein expression levels were correlated
with resistance to CDDP and PAC in three ovarian can-
cer cells (Fig. 1 and Fig. 3). Furthermore, PA-1 exhibited
relatively lower LXRα/β expression levels but increased
expression in response to cholesterol treatment (Fig. 3a
and c). Although our data is limited with three ovarian
cancer cell lines, these findings indicate that the choles-
terol treatment may enhance resistance in ovarian can-
cer cells through increased LXRα/β expression.
Cholesterol influences the expression of ABC trans-
porters by regulating their gene expression via nuclear
receptors (NRs). The NR superfamily comprises 48
members in the human genome and represents the lar-
gest currently known family of transcription factors [22].
To date, several NRs involved in the recognition of lipid
ligands have been shown to affect the gene expression of
human ABCB1 and ABCG2 transport function causing
multidrug resistance [46–48]. Likewise, cholesterol and
malignant ascites treatment upregulated cholesterol re-
ceptor, LXRα/β expression. Upregulation of MDR1 ex-
pression driven by cholesterol was significantly reversed
by silencing LXRα/β in PA-1 cells pre-treated with chol-
esterol, compared with that of untreated cells. Interest-
ingly, silencing LXRα/β did not significantly reduce the
expression of ABCG2 in PA-1 cells (Fig. 4b). Notably, si-
lencing LXRα/β, significantly reduced ovarian cancer cell
response to cholesterol induced resistance to CDDP and
PAC (Fig. 4c). It is also possible that stress signaling trans-
duction pathway transcriptionally activate ABCG2 expres-
sion [46]. In the case of malignant ascites treatment, our
group previously reported elevated levels of interleukin 6
(IL-6) in malignant ascites [6] and it has been reported
that IL-6 stimulates ABCG2 expression [49]. To explain
these differences, we postulate that there is another regu-
latory factor induced by both cholesterol and malignant
ascites which may indirectly activate ABCG2 expression,
independent of LXRα/β, a topic for future studies. Our re-
sults imply that inhibition of MDR1 alone reverses ac-
quired chemoresistance in ovarian cancer.
Conclusions
To date, no study has investigated a direct effect of cholesterol
on acquired chemoresistance in ovarian cancer. The results of
our research is novel in suggesting that cholesterol enriched in
malignant ascites contributes to poor prognosis by driving the
Fig. 7 High concentration of cholesterol in malignant ascites
correlates with shorter recurrence free survival (RFS). Comparison of
Kaplan-Meier curve for RFS between high and low cholesterol levels
in ascites, more than 70 mg/dL vs equal to or less than 70 mg/dL, in
ovarian cancer patients
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expression of these ABC transporters and confer chemoresis-
tance in ovarian cancer cells. As for the mechanism(s) by
which cholesterol levels are elevated in ascites, it needs more
studies. Collectively, our study underscores the importance
of future studies to investigate the mechanism(s) by which
cholesterol levels are elevated in ascites and how to manage
these in clinical setting.
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